The Role of Plasminogen Activator Inhibitor-1 Polymorphism, Factor-V-Leiden, and Prothrombin-20210 Mutations in Pulmonary Thromboembolism

被引：16

作者：

Oguzulgen, I. Kivilcim ^{[1
]}

Demirtas, Senay ^{[1
]}

Erkekol, Ferda Oner ^{[2
]}

Ekim, Numan ^{[1
]}

Demir, Nalan ^{[1
]}

Numanoglu, Numan ^{[2
]}

Ozel, Duygu ^{[3
]}

Ulu, Arzu ^{[3
]}

Akar, Nejat ^{[3
]}

机构：

[1] Gazi Univ, Sch Med, Dept Pulm Med, Besevler, Turkey

[2] Ankara Univ, Sch Med, Dept Pulm Med, TR-06100 Ankara, Turkey

[3] Ankara Univ, Sch Med, Dept Pediat Mol Genet, TR-06100 Ankara, Turkey

来源：

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | 2009年 / 15卷 / 01期

关键词：

pulmonary thromboembolism; genetics; plasminogen activator inhibitor-1; factor-V-Leiden; prothrombin-20210; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; 4G/5G POLYMORPHISM; PAI-1; GENE; G-A; PROMOTER; RISK; EMBOLISM; MECHANISMS; ARTERIAL;

D O I：

10.1177/1076029607305110

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Polymorphism in plasminogen activator inhibitor-1 gene is suggested to be associated with an increased risk of venous thromboembolism. The aim of this study was to investigate the association of plasminogen activator inhibitor-1 gene polymorphism and its coexistence with factor-V-Leiden and prothrombin-20210 mutations in pulmonary thromboembolism. The authors investigated plasminogen activator inhibitor-1 4G/5G polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in 143 pulmonary thromboembolism patients and 181 controls. Plasminogen activator inhibitor-1 4G/4G, 4G/5G, and 5G/5G gene polymorphisms and prothrombin-20210 mutations were not different between cases and controls. Factor-V-Leiden mutation was present in 21.0% and 7.7% of the cases and controls, respectively, P = .001. Neither different plasminogen activator inhibitor-1 genotypes and 4G allele nor coexistence of the allele with factor-V-Leiden or prothrombin-20210 was associated with the risk of recurrence. As a result, plasminogen activator inhibitor-1 gene polymorphism or its concomitant presence with mentioned mutations was not found to be associated with increased risk for pulmonary thromboembolism or recurrent disease in this study.

引用

页码：73 / 77

页数：5

共 22 条

[1] Effect of metylenetetrahydrofolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor V 1691 mutation in Turkish deep vein thrombosis patients
Akar, N
Akar, E
Akçay, R
Avcu, F
Yalcin, A
Cin, S
[J]. THROMBOSIS RESEARCH, 2000, 97 (03) : 163 - 167
[2] Akar N, 1998, AM J HEMATOL, V58, P249, DOI 10.1002/(SICI)1096-8652(199807)58:3<249::AID-AJH20>3.0.CO
[3] 2-3
[4] Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A
Akar, N
Yilmaz, E
Akar, E
Avcu, F
Yalçin, A
Cin, S
[J]. THROMBOSIS RESEARCH, 2000, 97 (04) : 227 - 230
[5] Allele 4G of gene PAI-I associated with prothrombin mutation G20210A increases the risk for venous thrombosis
Barcellona, D
Fenu, L
Cauli, C
Pisu, G
Marongiu, F
[J]. THROMBOSIS AND HAEMOSTASIS, 2003, 90 (06) : 1061 - 1064
[6] Francis CW, 2002, ARCH PATHOL LAB MED, V126, P1401
[7] The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism
Hooper, WC
Lally, C
Austin, H
Renshaw, M
Dilley, A
Wenger, NK
Phillips, DJ
Whitsett, C
Rawlins, P
Evatt, BL
[J]. THROMBOSIS RESEARCH, 2000, 99 (03) : 223 - 230
[8] Plasminogen activator inhibitor type-1 (part one): Basic mechanisms, regulation, and role for thromboembolic disease
Huber, K
[J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2001, 11 (03) : 183 - 193
[9] Junker R, 1998, THROMB HAEMOSTASIS, V80, P706
[10] Factor V Leiden, prothrombin 20210G → A, methylenetetrahydrofolate reductase 677C → T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous thromboembolism
Meglic, L
Stegnar, M
Milanez, T
Bozic, M
Peterlin, B
Peternel, P
Novak-Antolic, I
[J]. EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2003, 111 (02): : 157 - 163

← 1 2 3 →